"The urology centre" sign

Latest research

Every month we collate a selection of the latest clinically-relevant research to help you keep up to date with the most important developments in the field of prostate cancer.

Articles have been selected based on impact factor of the journal, relevance to UK clinical practice and general interest. You may be able to access the full text from your Trust's library service or via ATHENS registration. Information from PubMed explains other ways to access full text articles. 

Research round up from the clinic - top four articles from the last month:

See below for a more articles of interest published online in the last month (August and September 2014).

+

Advanced Disease

External beam radiotherapy plus single-fraction high dose rate brachytherapy in the treatment of locally advanced prostate cancer.

Boladeras A, Santorsa L, Gutierrez C, Martinez E, Pera J, Pino F, et al.

Radiother Oncol J. 2014 Aug [Epub ahead of print].

Clinical Outcome of Patients with Lymph Node-Positive Prostate Cancer following Radical Prostatectomy and Extended Sentinel Lymph Node Dissection.

Muck A, Langesberg C, Mugler M, Rahnenführer J, Wullich B, Schafhauser W.

Urol Int. 2014 Aug [Epub ahead of print].

+

Behaviour/Psychology

Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data.

Walker J, Hansen CH, Martin P, Symeonides S, Ramessur R, Murray G, et al.

Lancet Psychiatry. 2014 Aug [Epub ahead of print].

Obesity Affects the Biopsy-Mediated Detection of Prostate Cancer, Particularly High-Grade Prostate Cancer: A Dose-Response Meta-Analysis of 29,464 Patients.

Hu M-B, Liu S-H, Jiang H-W, Bai P-D, Ding Q.

PloS One. 2014;9(9):e106677.

Mental health outcomes in elderly men with prostate cancer.

Ravi P, Karakiewicz PI, Roghmann F, Gandaglia G, Choueiri TK, Menon M, et al.

Urol Oncol. 2014 Aug [Epub ahead of print].

+

BPH/Prostatitis/PIN

Change of nocturnal polyuria after holmium laser enucleation of the prostate in patients with benign prostatic hyperplasia.

Choi WS, Ku JH, Oh S-J, Kim SW, Paick J-S.

Urology. 2014 Sep;84(3):650–6.

A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction.

Hatzimouratidis K.

Ther Adv Urol. 2014 Aug;6(4):135–47.

A Population-Based Nested Case-Control Study: The Use of 5-Alpha-Reductase Inhibitors and the Increased Risk of Osteoporosis Diagnosis in Patients With Benign Prostate Hyperplasia.

Lin W-L, Hsieh Y-W, Lin C-L, Sung F-C, Wu C-H, Kao C-H.

Clin Endocrinol (Oxf). 2014 Aug [Epub ahead of print].

+

Diagnosis/Screening

Sex steroid hormone metabolism in relation to risk of aggressive prostate cancer.

Black A, Pinsky PF, Grubb RL, Falk RT, Hsing AW, Chu L, et al.

Cancer Epidemiol Biomark Prev. 2014 Sep [Epub ahead of print].

Procedural sedation and analgesia as an adjunct to periprostatic nerve block for prostate biopsy: A prospective randomized trial.

Doğanca T, Savsin A, Erdoğan S, Altindas F, Ozdemir F, Ekici B, et al.

J Clin Ultrasound JCU. 2014 Aug [Epub ahead of print].

The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level <2.5ng/ml.

Pashtan I, Chen M-H, D’Amico AV.

Cancer Epidemiol. 2014 Aug [Epub ahead of print].

Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial.

Saad F, de Bono J, Shore N, Fizazi K, Loriot Y, Hirmand M, et al.

Eur Urol. 2014 Aug [Epub ahead of print].

A Comparison of Web-Based Versus Print-Based Decision Aids for Prostate Cancer Screening: Participants’ Evaluation and Utilization.

Tomko C, Davis KM, Luta G, Krist AH, Woolf SH, Taylor KL.

J Gen Intern Med. 2014 Sep [Epub ahead of print].

+

Erectile Dysfunction

Effects of tadalafil once daily or on demand versus placebo on time to recovery of erectile function in patients after bilateral nerve-sparing radical prostatectomy.

Moncada I, de Bethencourt FR, Lledó-García E, Romero-Otero J, Turbi C, Büttner H, et al.

World J Urol. 2014 Aug [Epub ahead of print].

+

Genetics

The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer.

Akbari MR, Wallis CJD, Toi A, Trachtenberg J, Sun P, Narod SA, et al.

Br J Cancer. 2014 Aug [Epub ahead of print].

+

Prostatectomy

Robotic prostatectomy: the anesthetist’s view for robotic urological surgeries, a prospective study.

Oksar M, Akbulut Z, Ocal H, Balbay MD, Kanbak O.

Braz J Anesthesiol. 2014 Oct;64(5):307–13.

Transrectal ultrasound guidance for early transurethral recatheterization after radical prostatectomy.

Raber M.

J Ultrasound. 2014 Sep;17(3):203–6.

Robot-assisted versus other types of radical prostatectomy: population-based safety and cost comparison in Japan, 2012-2013

Sugihara T, Yasunaga H, Horiguchi H, Matsui H, Fujimura T, Nishimatsu H, et al.

Cancer Sci. 2014 Sep [Epub ahead of print]

+

Risk Factors

Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults.

Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L.

The Lancet; 384, 755-765.

Urinary Melatonin Levels, Sleep Disruption, and Risk of Prostate Cancer in Elderly Men.

Sigurdardottir LG, Markt SC, Rider JR, Haneuse S, Fall K, Schernhammer ES, et al.

Eur Urol. 2014 Aug [Epub ahead of print].

Diabetes mellitus and the risk of prostate cancer: an update and cumulative meta-analysis.

Jian Gang P, Mo L, Lu Y, Runqi L, Xing Z.

Endocr Res. 2014 Aug [Epub ahead of print].

+

Treatment

Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.

Fizazi K, Scher HI, Miller K, Basch E, Sternberg CN, Cella D, et al.

Lancet Oncol. 2014 Sep;15(10):1147–56.

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer.

Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al.

N Engl J Med. 2014 Sep

A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.

Azad AA, Leibowitz-Amit R, Eigl BJ, Lester R, Wells JC, Murray RN, et al.

The Prostate. 2014 Aug [Epub ahead of print].

Impact of (11)C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial.

Ceci F, Herrmann K, Castellucci P, Graziani T, Bluemel C, Schiavina R, et al.

Eur J Nucl Med Mol Imaging. 2014 Aug [Epub ahead of print].

Analysis of the cancer of the prostate risk assessment to predict for biochemical failure after external beam radiotherapy or prostate seed brachytherapy.

Delouya G, Krishnan V, Bahary J-P, Larrivée S, Taussky D.

Urology. 2014 Sep;84(3):629–33.

Extended Pelvic Lymph Node Dissection in Prostate Cancer Patients Previously Treated With Surgery for Lower Urinary Tract Symptoms.

Fossati N, Sjoberg DD, Capitanio U, Gandaglia G, Larcher A, Nini A, et al.

BJU Int. 2014 Aug [Epub ahead of print].

High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta-analysis of long-term follow-up.

Hou Z, Li G, Bai S.

J Cancer Res Clin Oncol. 2014 Aug [Epub ahead of print].

A Systematic Review of Hypofractionation for Primary Management of Prostate Cancer.

Koontz BF, Bossi A, Cozzarini C, Wiegel T, D’Amico A.

Eur Urol. 2014 Aug [Epub ahead of print].

Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.

Lane JA, Donovan JL, Davis M, Walsh E, Dedman D, Down L, et al.

Lancet Oncol. 2014 Sep;15(10):1109–18.

Loose versus stranded seeds in permanent prostate brachytherapy: Dosimetric comparison of intraoperative plans.

Major T, Agoston P, Fröhlich G, Baricza K, Szabo Z, Jorgo K, et al.

Phys Medica. 2014 Aug [Epub ahead of print].

Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.

Nadal R, Zhang Z, Rahman H, Schweizer MT, Denmeade SR, Paller CJ, et al.

The Prostate. 2014 Aug [Epub ahead of print].

Did prostate size affect the complication and outcome of plasmakinetic enucleation of the prostate?

Rao J-M, Xiao H-J, Ren Y-X, Ding P, He J, Yan Y-L, et al.

Int Urol Nephrol. 2014 Sep [Epub ahead of print].

Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances.

Singh BH, Gulley JL.

Ther Adv Vaccines. 2014 Sep;2(5):137–48.

Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies.

Zapatero A, González San Segundo C, Boladeras A, Gómez Caamaño A, López Torrecilla J, Maldonado X.

Clin Transl Oncol. 2014 Sep [Epub ahead of print].